According to a report by the news agency IANS, COVAXIN has proven its efficacy in animal studies and it produced a robust immune response in the animals.
More about COVAXIN animal studies
Bharat Biotech had tested COVAXIN on four groups comprising 20 rhesuses macaques (a species of Old World monkey) in each group. Under this study, these rhesuses macaques were given a “two-dose vaccination regimen of inactivated SARS-CoV-2 vaccine”. They were immunized with the vaccine at 0 and 14 days. Then after the 14 days of the 2nd dose of the vaccine, all these rhesuses macaques were exposed to the SARS-CoV-2 virus.
After the encounter with the virus, the results were recorded. As a result, it was found that the vaccine produced a robust immune response in these primates. As no signs and symptoms of pneumonia were observed in these primates.
More about COVAXIN
COVAXIN is India’s first indigenous COVID-19 vaccine which is being developed by Bharat Biotech in partnership with the Indian Council of Medical Research (ICMR). Bharat Biotech is a Telangana-based pharma company. COVAXIN is also running in the front row in the race to find a vaccine for Covid-19.
Coming to the type of vaccine, COVAXIN is an “inactivated” vaccine which means that it is developed by using the dead particles of coronavirus. Thus, an inactivated form of the virus that will build the immunity of the individual by making antibodies against the dead particles of the virus without the risk of getting infected or replicated.
At present COVAXIN is being tested at 12 institutes around the country. COVAXIN’s human trials were started in July after Bharat Biotech received a nod from the country’s drug regulatory body.
Earlier, COVAXIN was planned to be launched in the Indian market by August 15, however, experts later said that such a drug would not be possible till at least next year.